Sivelestat
- Generic Name
- Sivelestat
- Drug Type
- Small Molecule
- Chemical Formula
- C20H22N2O7S
- CAS Number
- 127373-66-4
- Unique Ingredient Identifier
- DWI62G0P59
- Background
Sivelestat has been used in trials studying the treatment of Acute Lung Injury and Respiratory Distress Syndrome, Adult.
- Indication
用于治疗伴有全身炎症反应综合征的急性肺损伤（ALI）和急性呼吸窘迫综合征（ARDS）。
Protective Effect of Sivelestat Sodium on ARDS in Patients With Sepsis
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- Southeast University, China
- Target Recruit Count
- 238
- Registration Number
- NCT04973670
- Locations
- 🇨🇳
Nanjing Zhong-Da Hospital, Southeast University, Nanjing, Jiangsu, China
Treatment of ARDS With Sivelestat Sodium
Phase 4
Recruiting
- Conditions
- Acute Respiratory Distress Syndrome
- Interventions
- Drug: Saline
- First Posted Date
- 2021-06-02
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Sichuan Provincial People's Hospital
- Target Recruit Count
- 324
- Registration Number
- NCT04909697
- Locations
- 🇨🇳
Sichuan provincial people's hospital, Chengdu, Sichuan Privince, China
Effect of Neutrophil Elastase Inhibitor on Lung Injury After Esophagectomy
- First Posted Date
- 2010-07-27
- Last Posted Date
- 2010-07-27
- Lead Sponsor
- Yokohama City University Medical Center
- Target Recruit Count
- 31
- Registration Number
- NCT01170845
- Locations
- 🇯🇵
Chikara Kunisaki, Yokohama, Kanagawa, Japan
Controlled Study of ONO-5046Na in Patients With Acute Respiratory Failure Associated With Community-Acquired Pneumonia
- First Posted Date
- 2007-01-01
- Last Posted Date
- 2012-06-13
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 174
- Registration Number
- NCT00417326
- Locations
- 🇯🇵
Chugoku Region, Chugoku, Japan
🇯🇵Hokkaido Region, Hokkaido, Japan
🇯🇵Hokuriku Region, Hokuriku, Japan
Study of Sivelestat Sodium Hydrate in Acute Lung Injury (ALI) Associated With Systemic Inflammatory Response Syndrome (SIRS) in Japan
Phase 4
Completed
- Conditions
- Systemic Inflammatory Response SyndromeAcute Lung Injury
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2015-04-23
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 649
- Registration Number
- NCT00219375
- Locations
- 🇯🇵
Kyushu Region Facility, Kyushu, Japan
🇯🇵Tohoku Region Facility, Tohoku, Japan
🇯🇵Kinki Region Facility, Kinki, Japan
A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury
Phase 1
Completed
- Conditions
- Respiratory Distress Syndrome, AdultAcute Lung Injury
- First Posted Date
- 2002-05-08
- Last Posted Date
- 2006-07-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 600
- Registration Number
- NCT00036062
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath